Intravacc B.V

Name ›

Address/P.O. Box › Postal Code/City › State › Contact Person › Telephone › Fax › Email › Website › Social Media › Number of Employees › Founded (year) › Type of Laboratory › Areas of Activity ›

Biological Patents ›

External ›

Collaborations

Request for ›

Further Collaborations Indivumed GmbH

Falkenried 88 – Bldg. D 20251 Hamburg Germany Prof. Dr med Hartmut Juhl (CEO) +49-40-4133-83-0 +49-40-4133-83-14 info@indivumed.com www.indivumed.com

LI

>250 2002 L2, S1 Service and partnering in the field of personalized cancer medicine; international standardisation of tissue, blood and clinical data collection in >60 cancer clinics in Europe, North-America and Asia; Multi-omics analysis of cancer tissue combining WGS with proteomics, phosphoproteomics, whole transcriptomics, and immunophenotyping; Data analysis using bioinformatics, artificial intelligence, and other tools. Various kinds of laboratory services for target and biomarker development. Indivumed has been granted several patents relating to cancer biomarkers. Indivumed has developed a unique collaborative network with leading cancer clinics in Europe, Asia, North- and South America, as well as with biopharmaceutical companies and academic institutions worldwide, including the Salk Institute, Georgetown University, University of Rochester Medical Center in the US, and the Astar Institute for Molecular and Cell Biology in Singapore. Indivumed intends to enter into strategic collaborations with industry partners for the joint development of cancer diagnostics and therapeutics.

Company overview

Indivumed is a global oncology company and a unique resource for accelerating cancer research and advancing precision oncology.

Founded in 2002 as one of the first companies in the field of personalized cancer therapy focused on the phenoytypic characterization of cancer in individual patients with the mission to unveil the complex mechanisms of cancer.

Cancer cells change expression profiles such as RNA, proteins, and phosphoproteins within minutes when tissue is removed from the body. This major challenge for researchers was resolutely addressed with the development and implementation of >130 SOPs since 2002 in the established Indivumed Global Clinical Network, which contains more than 60 cancer clinics and practices in Europe, North- and South-Amercia, and Asia.

With identical collection and processing standards for tissue and comprehensive clinical data from all kinds of solid tumors from tens of thousands of patients annually, Indivumed offers biospecimens and comprehensive clinical information of unparalleled depth and quality.

Services & Partnering

Based on this data, Indivumed offers specialized products and services, as well as development partnerships through two different business units.

IndivuServ At IndivuServ we provide a wide range of ISO-certified and GCP-compliant services based on our own biobank and state-of-the-art laboratories. These services include: › Access to biospecimens from our Indivumed Multiomics biobank, routine pathology biobank samples, and our Liquid biopsy biobank (longitudinal plasma) samples from cancer patients within our oncology practice network to perform for example nucleic acid testing (e.g. free circulating tumour DNA)

› Immunohistochemistry assay development including multiplex assays, in-house digital pathology, supporting target validation and companion diagnostics development › Further, research services of various kinds including immunophenotyping of tumours and drug testing in viable tissue cultures (e.g., immunooncology compound testin). We also offer the Spatial Transcriptomics technology to our customers

IndivuType IndivuType is a world leading discovery solution for personalized oncology that helps identify and validate novel disease mechanisms, drug targets, and biomarkers.

Unlike conventional, genomics-only approaches, IndivuType is based on the integration of deep multiomics data (genomics, transcriptomics, proteomics, and phosphoproteomics) with clinical and digital pathology data — all based on the highest quality biospecimens. Combined with the analytical power of our proprietary AI platform nRavel® this creates a superior discovery solution to understand cancer mechanisms and tumor progression, and to drive more effective and personalized drugs to treat cancer patients.

IndivuType pursues independent drug development activities — we can act as a service provider in early oncology research or be a trusted partner for AI and data driven development of novel cancer treatments.

Executive management team

Prof. Dr med Hartmut Juhl (CEO) Dr med Susanne Arbogast (CMO) Dr med Nils Clausnitzer (COO) Nils Schumacher (CLO)

Financing

Indivumed generates revenue through the commercialisation of its products and services. To build IndivuType, the first multi-omics cancer database, it has received funds from private investors, the European Investment Bank, and the European Regional Development Fund.